Mayne Pharma announced approximately an $888m equity raising to fund the acquisition of 37 and 5 FDA filed products from Teva Pharmaceutical Industries Ltd and Allergan PLC. The Offer is 1 for 1.725 pro-rata accelerated non-renounceable entitlement offer to raise approximately $601m, and a placement to institutional and sophisticated investors to raise approximately $287m. The offer price is $1.28.

A Retail Entitlement offer will open on 4th July 2016 to eligible shareholders.

For further information https://www.maynepharma.com/investor-relations/company-announcements/ .